# **Special Issue**

# Medical Advances in Viral Hemorrhagic Fever Research

### Message from the Guest Editors

Recent large outbreaks of Ebola and Marburg virus disease, Lassa fever, Crimean Congo hemorrhagic fever and severe fever with thrombocytopenia syndrome have afforded higher-resolution views at human clinical diseases historically referred to as "viral hemorrhagic Fevers." In addition to updating our understanding of the spectrum and severity of acute disease syndromes, recent encounters have renewed interest in, e.g., the role of pathogen-agnostic care in addition to virus-specific countermeasures, clinical seguelae after infection, and viral persistence potentially associated with inflammatory syndromes or risk of transmission and outbreak re-ignition. Although there are no FDA-approved medical countermeasures against these viral agents, increased funding, interest, and novel technologies have accelerated research and understanding of many medical aspects of these and other, more neglected viral hemorrhagic fever-causing pathogens. The present Special Issue covers a wide range of topics focusing on human clinical disease related to such "Medical Advances in Viral Hemorrhagic Fever Research".

### **Guest Editors**

Dr. Ian Crozier

Dr. Jens H. Kuhn

Dr. Sheli R. Radoshitzky

### Deadline for manuscript submissions

closed (31 July 2019)



## **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/18258

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





## Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

### **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

